This company has been marked as potentially delisted and may not be actively trading.

Arcellx (ACLX) Competitors

ACLX vs. BNTX, ROIV, MRNA, VTRS, and GMAB

Should you buy Arcellx stock or one of its competitors? MarketBeat compares Arcellx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcellx include BioNTech (BNTX), Roivant Sciences (ROIV), Moderna (MRNA), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Arcellx compare to BioNTech?

Arcellx (NASDAQ:ACLX) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

96.0% of Arcellx shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 8.4% of Arcellx shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BioNTech had 13 more articles in the media than Arcellx. MarketBeat recorded 13 mentions for BioNTech and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat BioNTech's score of 0.58 indicating that Arcellx is being referred to more favorably in the media.

Company	Overall Sentiment
Arcellx	Positive
BioNTech	Positive

Arcellx currently has a consensus price target of $111.87, suggesting a potential downside of 2.78%. BioNTech has a consensus price target of $130.60, suggesting a potential upside of 42.10%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Arcellx has higher earnings, but lower revenue than BioNTech. Arcellx is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
BioNTech	$3.25B	7.16	-$1.29B	-$5.88	N/A

BioNTech has a net margin of -44.39% compared to Arcellx's net margin of -1,027.26%. BioNTech's return on equity of -5.30% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
BioNTech	-44.39%	-5.30%	-4.62%

Summary

BioNTech beats Arcellx on 11 of the 16 factors compared between the two stocks.

How does Arcellx compare to Roivant Sciences?

Arcellx (NASDAQ:ACLX) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

In the previous week, Roivant Sciences had 8 more articles in the media than Arcellx. MarketBeat recorded 8 mentions for Roivant Sciences and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Roivant Sciences' score of 0.76 indicating that Arcellx is being referred to more favorably in the media.

Company	Overall Sentiment
Arcellx	Positive
Roivant Sciences	Positive

Roivant Sciences has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A
Roivant Sciences	$29.05M	725.68	-$171.98M	-$1.17	N/A

Arcellx currently has a consensus price target of $111.87, suggesting a potential downside of 2.78%. Roivant Sciences has a consensus price target of $30.55, suggesting a potential upside of 3.72%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

96.0% of Arcellx shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 8.4% of Arcellx shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Arcellx has a net margin of -1,027.26% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcellx	-1,027.26%	-55.42%	-36.24%
Roivant Sciences	-6,079.94%	-19.04%	-18.15%

Summary

Roivant Sciences beats Arcellx on 13 of the 17 factors compared between the two stocks.

How does Arcellx compare to Moderna?

Moderna (NASDAQ:MRNA) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Moderna had 33 more articles in the media than Arcellx. MarketBeat recorded 33 mentions for Moderna and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Moderna's score of 0.65 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Moderna	Positive
Arcellx	Positive

Arcellx has lower revenue, but higher earnings than Moderna. Arcellx is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	9.02	-$2.82B	-$8.15	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

Moderna presently has a consensus price target of $35.73, suggesting a potential downside of 28.69%. Arcellx has a consensus price target of $111.87, suggesting a potential downside of 2.78%. Given Arcellx's stronger consensus rating and higher probable upside, analysts plainly believe Arcellx is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

75.3% of Moderna shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 10.8% of Moderna shares are owned by insiders. Comparatively, 8.4% of Arcellx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Moderna has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Moderna has a net margin of -143.55% compared to Arcellx's net margin of -1,027.26%. Moderna's return on equity of -26.64% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Arcellx	-1,027.26%	-55.42%	-36.24%

Summary

Moderna beats Arcellx on 9 of the 17 factors compared between the two stocks.

How does Arcellx compare to Viatris?

Viatris (NASDAQ:VTRS) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Viatris currently has a consensus price target of $15.71, indicating a potential downside of 8.74%. Arcellx has a consensus price target of $111.87, indicating a potential downside of 2.78%. Given Arcellx's higher possible upside, analysts plainly believe Arcellx is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Viatris has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

In the previous week, Viatris had 16 more articles in the media than Arcellx. MarketBeat recorded 16 mentions for Viatris and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Viatris' score of 0.64 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Viatris	Positive
Arcellx	Positive

Arcellx has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Arcellx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.40	-$3.51B	-$0.26	N/A
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

79.9% of Viatris shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 0.3% of Viatris shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Viatris has a net margin of -2.04% compared to Arcellx's net margin of -1,027.26%. Viatris' return on equity of 19.04% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Arcellx	-1,027.26%	-55.42%	-36.24%

Summary

Viatris beats Arcellx on 9 of the 17 factors compared between the two stocks.

How does Arcellx compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Genmab A/S has a net margin of 21.05% compared to Arcellx's net margin of -1,027.26%. Genmab A/S's return on equity of 15.34% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Arcellx	-1,027.26%	-55.42%	-36.24%

In the previous week, Genmab A/S had 10 more articles in the media than Arcellx. MarketBeat recorded 10 mentions for Genmab A/S and 0 mentions for Arcellx. Arcellx's average media sentiment score of 1.07 beat Genmab A/S's score of 0.71 indicating that Arcellx is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Positive
Arcellx	Positive

Genmab A/S currently has a consensus price target of $39.07, indicating a potential upside of 45.06%. Arcellx has a consensus price target of $111.87, indicating a potential downside of 2.78%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.83
Arcellx	1 Sell rating(s)	16 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.11

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.51	$963M	$1.32	20.41
Arcellx	$22.29M	301.95	-$228.93M	-$4.07	N/A

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genmab A/S has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Arcellx has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

Summary

Genmab A/S beats Arcellx on 13 of the 17 factors compared between the two stocks.

Get Arcellx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACLX vs. The Competition

Export

Metric	Arcellx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.73B	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-28.27	18.77	20.85	25.56
Price / Sales	301.95	263.59	543.57	72.25
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	16.53	6.77	9.87	6.72
Net Income	-$228.93M	$24.11M	$3.55B	$333.62M

Arcellx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACLX Arcellx	2.5092 of 5 stars	$115.07 flat	$111.87 -2.8%	+97.5%	$6.73B	$22.29M	N/A	80	High Trading Volume
BNTX BioNTech	3.8392 of 5 stars	$99.35 +1.9%	$133.13 +34.0%	-2.4%	$24.67B	$3.25B	N/A	7,807	Analyst Forecast Buyback Announcement
ROIV Roivant Sciences	2.3431 of 5 stars	$28.36 +1.9%	$30.55 +7.7%	+171.6%	$19.92B	$29.05M	N/A	860	Positive News
MRNA Moderna	1.4756 of 5 stars	$47.30 +4.3%	$35.73 -24.5%	+97.8%	$17.92B	$1.94B	N/A	4,700
VTRS Viatris	2.5693 of 5 stars	$15.20 +1.1%	$14.67 -3.5%	+97.6%	$17.51B	$14.30B	N/A	30,000	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACLX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcellx (ACLX) Competitors